首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2103146

抗菌藥物敏感性測試市場：策略性洞察與預測（2026-2035）

Antimicrobial Susceptibility Testing Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年07月09日 | 出版商:

Knowledge Sourcing Intelligence | 英文 178 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

抗菌藥物敏感性測試市場預計將從 2026 年的 56.3 億美元成長到 2035 年的 120.3 億美元，複合年成長率為 8.8%。

抗菌藥物敏感性檢測 (AST) 市場正經歷顯著的變革，其驅動力是日益嚴重的抗菌藥物抗藥性威脅以及全球對負責任的抗生素管理的需求。這一市場演變的特點是從傳統的手動方法轉向高度自動化的系統和快速分子診斷，從而提供更快、更標準化的結果。醫療系統正擴大採用自動化抗菌藥物敏感性檢測 (AST) 平台，以簡化臨床微生物學的工作流程，縮短檢測結果報告時間，並提高診斷準確性。隨著多重抗藥性病原體的日益流行，對快速、準確的敏感性檢測的需求持續成長，以支持靶向抗生素治療並改善患者預後。國家抗菌藥物使用計畫以及由世界衛生組織 (WHO) 和美國疾病管制與預防中心 (CDC) 等機構主導的全球計劃正在推動 AST 的更廣泛應用，並促進全球市場成長。檢查室自動化、人工智慧和數位微生物學的整合，使醫院微生物檢查室、診斷中心和公共衛生機構能夠更有效率地處理日益成長的檢測量。隨著對快速分子水平抗藥性檢測技術、人工智慧驅動的結果解釋和整合實驗室資訊系統的大量投資，藥敏試驗正在成為現代感染疾病控制的重要組成部分。

市場促進因素

多重抗藥性病原體的日益普及是抗菌藥物敏感性檢測市場的主要促進因素。醫療機構正在部署先進的抗菌藥物敏感性檢測系統，以支援標靶抗生素治療並改善患者預後。抗菌藥物抗藥性日益嚴重，使得臨床、公共衛生和製藥領域對快速、準確的藥敏試驗的需求持續成長的需求。感染疾病、感染疾病和醫療相關感染疾病的增加，也使得快速病原體鑑定和藥敏試驗的需求日益迫切。這一趨勢正在擴大抗菌藥物敏感性檢測在醫院、診斷檢查室和公共衛生機構的應用。臨床檢查室正在投資自動化抗菌藥物敏感性檢測平台，以簡化工作流程、縮短結果報告時間並提高診斷準確性。實驗室自動化正成為重要的成長要素，尤其是在醫療量大的醫療機構中，標準化檢測對於有效合理使用抗菌藥物至關重要。國家抗菌藥物使用計劃和全球計劃正在推動抗菌藥物敏感性檢測的更廣泛應用。加強法律規範、改善公共衛生監測系統以及為抗菌素抗藥性研究提供資金，正在加速各種醫療保健系統採用抗菌藥物敏感性試驗 (AST) 技術。

市場限制因素

自動化藥敏試驗設備和分子診斷平台需要大量資金投入，限制了其在中小檢查室的應用。設備和基礎設施的高昂初始成本是資源匱乏地區實驗室的一大障礙。操作先進的微生物分析儀需要具備微生物學、分子診斷和檢查室自動化專業知識的專業人員，這在許多地區造成了人才短缺的挑戰。合格人員的短缺限制了藥敏試驗服務的擴充性。體外診斷醫療設備嚴格的監管要求增加了產品開發時間和商業化成本，延緩了創新技術的市場准入。嚴格的核准流程也給小規模診斷設備製造商帶來了挑戰。許多中低收入國家缺乏足夠的檢查室基礎設施、資金和診斷能力，限制了先進藥敏試驗技術的廣泛應用。這些基礎設施的差距阻礙了受感染疾病影響最嚴重地區的市場滲透。

分析：依產品類型
- 裝置
- 試劑和耗材
- 軟體
分析：按技術平台
- 自動化抗菌藥物敏感性測試（AST）系統
- 手動AST方法
- 基於分子生物學的AST方法
- 肉湯微量稀釋法
- 紙錠擴散法
- 梯度擴散法（E-test）
分析：依樣本類型
- 血
- 尿
- 呼吸道檢體
- 傷口檢體
- 其他臨床檢體
分析：透過應用
- 臨床診斷
- 藥物調查
- 食品安全檢查
- 獸醫診斷

第9章全球抗菌藥物敏感性檢測市場：細分市場分析

依產品
- 裝置
- 試劑和耗材
- 軟體
透過方法
- 自動化藥敏試驗
- 手動藥敏試驗
透過技術
- 肉湯微量稀釋法
- 紙錠擴散法
- 梯度擴散法
- 快速分子診斷方法
- 其他技術
透過使用
- 臨床診斷
- 藥物發現與開發
- 流行病學監測
- 食品和飲料檢測
- 獸醫診斷
最終用戶
- 醫院
- 診斷檢查室
- 製藥和生物技術公司
- 學術研究機構
- 食品檢驗機構
- 獸醫檢測實驗室

第10章全球抗菌藥物敏感性檢測市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球抗菌藥物敏感性檢測市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
荷蘭
日本
中國
印度
韓國
澳洲
巴西
墨西哥
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

bioMerieux
Becton, Dickinson and Company
Thermo Fisher Scientific Inc.
Danaher Corporation
Bruker Corporation
QIAGEN NV
Bio-Rad Laboratories, Inc.
Accelerate Diagnostics, Inc.
Beckman Coulter, Inc.
Merlin Diagnostika GmbH
Hardy Diagnostics
Liofilchem Srl
HiMedia Laboratories Pvt. Ltd.
Creative Diagnostics
Mast Group Ltd.

第14章：全球抗菌藥物敏感性檢測市場：商業預測分析

第15章：投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009037

The Antimicrobial Susceptibility Testing Market is set to reach USD 12.03 billion in 2035, growing at a CAGR of 8.8% from USD 5.63 billion in 2026.

The antimicrobial susceptibility testing market is undergoing significant transformation driven by the escalating threat of antimicrobial resistance and the global imperative for responsible antibiotic stewardship. The market's evolution is characterized by a shift from traditional manual methods toward advanced automated systems and rapid molecular diagnostics that deliver faster, more standardized results. Healthcare systems are increasingly adopting automated AST platforms to improve workflow efficiency, reduce turnaround times, and enhance diagnostic accuracy in clinical microbiology. The rising prevalence of multidrug-resistant pathogens is creating sustained demand for rapid and accurate susceptibility testing to support targeted antibiotic therapy and improve patient outcomes. National antimicrobial stewardship programs and global initiatives led by organizations such as the WHO and CDC are encouraging wider implementation of AST, strengthening market growth worldwide. The convergence of laboratory automation, artificial intelligence, and digital microbiology is enabling more efficient management of increasing testing volumes across hospital microbiology laboratories, diagnostic centers, and public health institutions. The market is witnessing significant investment in rapid molecular resistance detection technologies, AI-powered result interpretation, and integrated laboratory information systems, positioning AST as a critical component of modern infectious disease management.

Market Drivers

The increasing prevalence of multidrug-resistant pathogens represents the primary driver for the antimicrobial susceptibility testing market. Healthcare providers are adopting advanced AST systems to support targeted antibiotic therapy and improve patient outcomes. The growing burden of antimicrobial resistance is creating sustained demand for rapid and accurate susceptibility testing across clinical, public health, and pharmaceutical settings. The rising number of bacterial, fungal, and healthcare-associated infections has increased the need for timely pathogen identification and susceptibility testing. This trend is expanding the utilization of AST across hospitals, diagnostic laboratories, and public health institutions. Clinical laboratories are investing in automated AST platforms to improve workflow efficiency, reduce turnaround time, and enhance diagnostic accuracy. Laboratory automation is becoming a key growth driver, particularly in high-volume healthcare facilities where standardized testing is essential for effective antimicrobial stewardship. National antimicrobial stewardship programs and global initiatives are encouraging wider implementation of antimicrobial susceptibility testing. Strengthened regulatory oversight, public health surveillance systems, and funding for antimicrobial resistance research continue to accelerate the adoption of AST technologies across diverse healthcare systems.

Market Restraints

Automated susceptibility testing instruments and molecular diagnostic platforms require significant capital investment, limiting adoption among small and medium-sized laboratories. The substantial upfront costs for equipment and infrastructure create barriers for facilities in resource-constrained settings. Operation of advanced microbiology analyzers requires trained personnel with expertise in microbiology, molecular diagnostics, and laboratory automation, creating workforce challenges in many regions. The shortage of qualified professionals limits the scalability of AST services. Strict regulatory requirements for in vitro diagnostic devices increase product development timelines and commercialization costs, delaying market entry for innovative technologies. The rigorous approval processes create challenges for smaller diagnostic manufacturers. Many low- and middle-income countries lack adequate laboratory infrastructure, funding, and diagnostic capacity, restricting widespread implementation of advanced AST technologies. These infrastructure gaps limit market penetration in regions with the highest burden of infectious diseases.

Technology and Segment Insights

The technology landscape is characterized by the growing dominance of automated susceptibility testing systems. Automated AST provides standardized, reproducible, and rapid antimicrobial susceptibility results with minimal manual intervention. Large hospitals and reference laboratories increasingly prefer automated systems to improve laboratory efficiency and reduce turnaround times. Rapid molecular methods are experiencing the fastest growth because they enable early detection of antimicrobial resistance genes and significantly reduce diagnostic turnaround times. Broth microdilution remains the reference standard because it provides highly accurate minimum inhibitory concentration determination and supports standardized clinical decision-making. Disk diffusion continues to be widely used owing to its simplicity, affordability, and extensive clinical acceptance. Gradient diffusion methods provide quantitative MIC values while maintaining operational flexibility for routine laboratories. The segment analysis reveals that reagents and consumables account for the largest share because AST procedures require continuous use of susceptibility panels, culture media, antimicrobial disks, broth reagents, quality control materials, and testing kits. Instruments generate significant capital revenue through automated AST analyzers and integrated microbiology platforms. Software adoption is increasing as laboratories implement digital workflow management, automated result interpretation, antimicrobial stewardship support, and laboratory information management systems. Clinical diagnostics represent the leading application segment, with hospital microbiology laboratories remaining the largest end users. Pharmaceutical and biotechnology companies are increasingly adopting AST in drug discovery and development. Epidemiological surveillance and veterinary diagnostics are expanding applications, driven by growing antimicrobial resistance monitoring needs.

Competitive and Strategic Outlook

The competitive landscape features established microbiology diagnostics companies alongside specialized molecular testing providers. bioMerieux is a global leader through its VITEK platform, automated microbiology systems, and antimicrobial stewardship solutions, continuing to expand its microbiology portfolio through continuous innovation. Becton, Dickinson and Company provides comprehensive microbiology laboratory solutions, including automated identification and susceptibility testing systems, specimen management technologies, and antimicrobial resistance surveillance platforms. Thermo Fisher Scientific offers microbiology reagents, molecular diagnostics, sequencing technologies, laboratory automation solutions, and antimicrobial susceptibility testing products supporting clinical laboratories worldwide. Danaher, through Beckman Coulter, develops laboratory automation and diagnostic workflow solutions that enhance microbiology laboratory productivity. Bruker continues expanding its MALDI-TOF-based microbiology solutions by integrating rapid organism identification with antimicrobial susceptibility testing workflows. QIAGEN specializes in molecular diagnostics, syndromic testing, and antimicrobial resistance gene detection technologies supporting rapid susceptibility testing. Bio-Rad develops molecular diagnostic assays, quality control products, and laboratory systems supporting infectious disease diagnostics. Accelerate Diagnostics focuses on rapid pathogen identification and phenotypic antimicrobial susceptibility testing technologies that significantly reduce time-to-result. Companies are pursuing product portfolio expansion through innovation in automated AST platforms, rapid molecular resistance detection, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers and healthcare systems are increasing, driven by the need for antimicrobial stewardship and resistance surveillance. Recent key developments include bioMerieux expanding its VITEK automated microbiology platform with enhanced antimicrobial susceptibility testing capabilities. BD introduced workflow improvements for automated microbiology laboratories aimed at strengthening antimicrobial stewardship initiatives. Thermo Fisher Scientific expanded its clinical microbiology portfolio through new molecular diagnostic solutions for antimicrobial resistance detection. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The antimicrobial susceptibility testing market is positioned for sustained growth driven by the convergence of rising antimicrobial resistance, laboratory automation, and global stewardship initiatives. The transition from manual methods toward automated and molecular AST platforms represents a fundamental shift in clinical microbiology. While challenges related to capital investment, workforce shortages, and regulatory complexity persist, strategic investments in technology, innovation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with antimicrobial susceptibility testing evolving into an essential component of precision infectious disease management, supporting targeted antibiotic therapy, resistance surveillance, and public health initiatives worldwide.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Antimicrobial Susceptibility Testing Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Antimicrobial Resistance (AMR) Burden Analysis
3.8 Testing Volume Analysis
3.9 Laboratory Workflow Analysis
3.10 Clinical Significance of Antimicrobial Susceptibility Testing

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies
6.2 Product Innovation
6.3 Diagnostic Pipeline Analysis
6.4 Automation in Antimicrobial Susceptibility Testing
6.5 Artificial Intelligence and Data Analytics Integration
6.6 Digital Microbiology and Laboratory Informatics
6.7 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Antimicrobial Susceptibility Testing Market Landscape Analysis

8.1 Analysis by Product Type
- 8.1.1 Instruments
- 8.1.2 Reagents & Consumables
- 8.1.3 Software
8.2 Analysis by Technology Platform
- 8.2.1 Automated AST Systems
- 8.2.2 Manual AST Methods
- 8.2.3 Molecular AST Methods
- 8.2.4 Broth Microdilution
- 8.2.5 Disk Diffusion
- 8.2.6 Gradient Diffusion (E-test)
8.3 Analysis by Sample Type
- 8.3.1 Blood
- 8.3.2 Urine
- 8.3.3 Respiratory Samples
- 8.3.4 Wound Samples
- 8.3.5 Other Clinical Samples
8.4 Analysis by Application
- 8.4.1 Clinical Diagnostics
- 8.4.2 Pharmaceutical Research
- 8.4.3 Food Safety Testing
- 8.4.4 Veterinary Diagnostics

9. Global Antimicrobial Susceptibility Testing Market Segment Analysis (2021-2035)

9.1 By Product
- 9.1.1 Instruments
- 9.1.2 Reagents & Consumables
- 9.1.3 Software
9.2 By Method
- 9.2.1 Automated Susceptibility Testing
- 9.2.2 Manual Susceptibility Testing
9.3 By Technology
- 9.3.1 Broth Microdilution
- 9.3.2 Disk Diffusion
- 9.3.3 Gradient Diffusion
- 9.3.4 Rapid Molecular Methods
- 9.3.5 Other Technologies
9.4 By Application
- 9.4.1 Clinical Diagnostics
- 9.4.2 Drug Discovery & Development
- 9.4.3 Epidemiological Surveillance
- 9.4.4 Food & Beverage Testing
- 9.4.5 Veterinary Diagnostics
9.5 By End User
- 9.5.1 Hospitals
- 9.5.2 Diagnostic Laboratories
- 9.5.3 Pharmaceutical & Biotechnology Companies
- 9.5.4 Academic & Research Institutes
- 9.5.5 Food Testing Laboratories
- 9.5.6 Veterinary Laboratories

10. Global Antimicrobial Susceptibility Testing Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Antimicrobial Susceptibility Testing Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Netherlands
11.9 Japan
11.10 China
11.11 India
11.12 South Korea
11.13 Australia
11.14 Brazil
11.15 Mexico
11.16 Saudi Arabia
11.17 South Africa

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 bioMerieux
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Becton, Dickinson and Company
- 13.2.1 Company Overview
- 13.2.2 Financials
- 13.2.3 Product Portfolio
- 13.2.4 Recent Developments
13.3 Thermo Fisher Scientific Inc.
- 13.3.1 Company Overview
- 13.3.2 Financials
- 13.3.3 Product Portfolio
- 13.3.4 Recent Developments
13.4 Danaher Corporation
- 13.4.1 Company Overview
- 13.4.2 Financials
- 13.4.3 Product Portfolio
- 13.4.4 Recent Developments
13.5 Bruker Corporation
- 13.5.1 Company Overview
- 13.5.2 Financials
- 13.5.3 Product Portfolio
- 13.5.4 Recent Developments
13.6 QIAGEN N.V.
- 13.6.1 Company Overview
- 13.6.2 Financials
- 13.6.3 Product Portfolio
- 13.6.4 Recent Developments
13.7 Bio-Rad Laboratories, Inc.
- 13.7.1 Company Overview
- 13.7.2 Financials
- 13.7.3 Product Portfolio
- 13.7.4 Recent Developments
13.8 Accelerate Diagnostics, Inc.
- 13.8.1 Company Overview
- 13.8.2 Financials
- 13.8.3 Product Portfolio
- 13.8.4 Recent Developments
13.9 Beckman Coulter, Inc.
- 13.9.1 Company Overview
- 13.9.2 Financials
- 13.9.3 Product Portfolio
- 13.9.4 Recent Developments
13.10 Merlin Diagnostika GmbH
- 13.10.1 Company Overview
- 13.10.2 Financials
- 13.10.3 Product Portfolio
- 13.10.4 Recent Developments
13.11 Hardy Diagnostics
- 13.11.1 Company Overview
- 13.11.2 Financials
- 13.11.3 Product Portfolio
- 13.11.4 Recent Developments
13.12 Liofilchem S.r.l.
- 13.12.1 Company Overview
- 13.12.2 Financials
- 13.12.3 Product Portfolio
- 13.12.4 Recent Developments
13.13 HiMedia Laboratories Pvt. Ltd.
- 13.13.1 Company Overview
- 13.13.2 Financials
- 13.13.3 Product Portfolio
- 13.13.4 Recent Developments
13.14 Creative Diagnostics
- 13.14.1 Company Overview
- 13.14.2 Financials
- 13.14.3 Product Portfolio
- 13.14.4 Recent Developments
13.15 Mast Group Ltd.
- 13.15.1 Company Overview
- 13.15.2 Financials
- 13.15.3 Product Portfolio
- 13.15.4 Recent Developments